Analytical Data
-
基因名
VEGFR-3/FLT4
-
简介
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
别名
Vascular endothelial growth factor receptor 3; VEGFR-3; FLT-4
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P35916-2
-
表达区间
Y25-I776
-
蛋白长度
Partial
-
分子量
130 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VEGFR-3, also known as FLT4, is a receptor tyrosine kinase primarily involved in the regulation of lymphangiogenesis and blood vessel development. Its significance has increased in various fields of biomedical research, particularly in cancer biology, as it plays a crucial role in tumor metastasis and the formation of lymphatic vessels. The activation of VEGFR-3 by its ligands, mainly VEGF-C and VEGF-D, drives lymphatic endothelial cell proliferation and migration, which are critical processes in both normal physiological and pathological conditions. Understanding the molecular mechanisms regulating VEGFR-3 can provide insights into novel therapeutic strategies for cancer and lymphatic disorders. The production and characterization of recombinant VEGFR-3/FLT4 protein enable researchers to study its structure-function relationships and interactions with ligands and downstream signaling pathways. Furthermore, recombinant VEGFR-3 can be utilized in various assays to screen potential inhibitors, which could lead to the development of new treatments targeting lymphangiogenesis in diseases such as cancer, lymphedema, and inflammation. Thus, the study of VEGFR-3/FLT4 recombinant protein is essential for advancing our knowledge of lymphatic biology and developing innovative therapeutic approaches.
